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Serum response factor modulates neuron survival
during peripheral axon injury
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Abstract
Background: The transcription factor SRF (serum response factor) mediates neuronal survival in vitro. However, data
available so far suggest that SRF is largely dispensable for neuron survival during physiological brain function.
Findings: Here, we demonstrate that upon neuronal injury, that is facial nerve transection, constitutively-active SRF-
VP16 enhances motorneuron survival. SRF-VP16 suppressed active caspase 3 abundance in vitro and enhanced
neuron survival upon camptothecin induced apoptosis. Following nerve fiber injury in vitro, SRF-VP16 improved
survival of neurons and re-growth of severed neurites. Further, SRF-VP16 enhanced immune responses (that is
microglia and T cell activation) associated with neuronal injury in vivo. Genome-wide transcriptomics identified
target genes associated with axonal injury and modulated by SRF-VP16.
Conclusion: In sum, this is a first report describing a neuronal injury-related survival function for SRF.
Keywords: Facial nerve, Immune cell, Motorneuron, Regeneration, SRF, Axon, Microglia
Background
The gene regulator SRF modulates multiple aspects of
neuronal motility. In SRF-deficient mice, cell migration,
neurite outgrowth, branching, growth cone shape and axon
guidance are impaired. In turn, constitutively-active SRF-
VP16, a fusion protein of SRF and the viral VP16 transacti-
vation domain, enhances neuronal motility [1]. Thus, SRF’s
impact on physiological neuronal motility might proof
beneficial also during axonal regeneration, that is the stimu-
lation of regrowth of severed nerve fibers.
In addition to cell differentiation, SRF has been impli-
cated in cell survival of various cell types including
hepatocytes [2], thymocytes [3], heart cells [4], and dur-
ing embryogenesis [5]. In embryonic stem cells lacking
SRF apoptosis was strongly upregulated [4]. The latter
result is in line with downregulation of the antiapoptotic
protein Bcl-2 upon SRF-deficiency. Bcl-2 was identified
as SRF target gene in the same study [5]. In primary cor-
tical neurons, SRF overexpression mediates BDNF-
dependent cell survival in various paradigms of neuronal
injury [6]. Also, SRF conveys expression of the immedi-
ate early gene (IEG) Cyr61 during neuronal cell death
[7].
SRF operates through interaction with co-factors of
the MRTF (myocardin-related transcription factors) and
TCF (ternary complex factors) family. Through inter-
action with TCFs SRF can mediate an IEG response of
for example c-fos, Egr1 and Arc. IEGs are well-estab-
lished molecular switches of cell survival vs. cell death
[8]. Further, while interacting with MRTFs SRF directs
expression of actin isoforms (Acta, Actb, Actc) or actin-
binding proteins (for example tropomyosin, calponin and
gelsolin) thereby regulating cytoskeletal dynamics [1,9].
Similar to SRF, MRTF-A and the TCF Elk-1 enhance cell
survival of primary neurons [6,10–13] and non-neuronal
cells [14]. In opposite to primary neurons, cell survival and
apoptosis are not overtly altered during physiological ner-
vous system development as revealed by SRF-deficient mice
[15–17]. Indeed, apoptosis was only elevated in the subven-
tricular zone of SRF-deficient mice [15] but not documen-
ted in for example cortical, hippocampal, striatal and
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peripheral neurons [15–17]. This suggests that SRF is not a
major neuronal survival regulator during physiological
brain development.
As mentioned above, SRF and co-factors mediate in-
jury-related neuronal survival in vitro. Thus, an in vivo
function of SRF in neuronal survival (which has not
been demonstrated so far) might become apparent dur-
ing application of neuronal injury.
Here we applied facial nerve injury in adult mice to inves-
tigate a role of SRF-VP16 in survival of facial motorneurons
in vivo. In mice, the bilateral facial nerve innervates muscles
regulating whisker pad and eyelid movements, for example
[18]. Facial nerve axotomy is a model system for studying
motorneuron survival, axonal regeneration as well as
neuron and immune cell interactions during neuronal in-
jury. We observed an SRF-VP16 dependent increase in
motorneuron survival in vivo. In addition, SRF-VP16
enhanced outgrowth and survival of transected primary
neurons in vitro. Mechanistically this SRF-VP16 function
involves suppression of active caspase 3 expression in vitro
and increased microglia and T cell activation around trans-
ected motorneurons in vivo. Finally, using transcriptomics,
we provide axonal injury-induced and SRF-VP16 modu-




The facial nerve transection was performed as described in
[19]. Adult wild-type mice (>2 month) were anaesthetized,
a skin incision was made behind the left ear and the facial
nerve was exposed. In experiments with no virus applica-
tion, the nerve was transected with small microscissors
about 2 mm posterior to the foramen stylomastoideum.
For viral infection, 1 μl virus was injected into the facial
nerve using a 26 G Hamilton syringe. Afterwards, the nerve
was transected and another 1 μl of virus was injected into
the nerve stump. Of note, this virus injection with a syringe
causes already a facial nerve lesion. Therefore it is only pos-
sible to delineate SRF-VP16 specific effects on the basis of
experiments employing control virus, SRF-ΔMADS-VP16.
Cesium-chloride purified SRF-VP16 (4.6 × 1012 PFU/mL)
and SRF-ΔMADS-VP16 (4.9 × 1012 PFU/mL) adenoviral
particles were purchased from Vector Biolabs. Both viruses
drive GFP expression via a second CMV promoter. Ab-
sence of eyelid closure and whisker movement ensured suc-
cessful nerve transection. All experiments are in
accordance with institutional regulations by the local ani-
mal ethical committee (Regierungspräsidium Tübingen).
Histology
Brains were fixed in 4% PFA/PBS overnight followed by
preparation of 60 μm vibratome slices. Immunohistochem-
istry was performed using Biotin-conjugated secondary
antibodies (1:500; Vector) and peroxidase-based detection
systems using the ABC complex (Vector) and DAB as sub-
strate. Primary antibodies included anti-IBA1 (rabbit, 1:500;
Wako) and anti-CD3 (mouse, 1:1,000; Dr. G. Jung,
Tübingen University).
Cell biology
Primary neurons were prepared as before [20]. Hippocam-
pal neurons derived from wild-type or SRF-deficient mice
[15] were electroporated with SRF-VP16 or SRF-ΔMADS-
VP16 and cultured for 72 h. Neurons were electroporated
with 3 μg of the plasmids using Amaxa nucleofection
resulting on average in 30% to 40% transfected cells. Neu-
rons were stimulated for 1 h with myelin (12 μg/ml). Pro-
tein lysates were prepared as before [21]. Rabbit anti-active
caspase 3 (Cell Signaling; 1:1,000) and mouse anti-GAPDH
(Acris; 1:50,000) antibodies were used.
For neuronal injury experiments in vitro, hippocampal
neurons were grown on poly-L-lysine and laminin coated
video dishes. One neurite/neuron was cut with a micro-
scalpel driven by an InjectMan® NI 2 Micromanipulator
(Eppendorf). The cell reaction was monitored in a life cell
imaging set-up (37°C, 5% CO2; Zeiss, Axiovert 200 M)
every 5 min for a total of 6 h. Ten neurons/condition in 13
independent experiments were evaluated.
Neurons were infected with 1 × 108 PFU/ml adenoviral
particles expressing GFP alone, SRF-ΔMADS-VP16:GFP
or SRF-VP16:GFP 5 h after plating. The next day, cul-
tures were treated overnight (17 h) with camptothecin at
0.1, 1, or 3 μΜ followed by immunocytochemistry.
Immunocytochemistry
Cells were fixed for 15 min in 4% PFA/5% Sucrose/PBS,
permeabilized for 5 min in 0.1% Triton-X-100/PBS and
blocked for 30 min in 2% BSA/PBS. Primary antibodies
were incubated for 2 h at room temperature as follows:
rabbit anti-active caspase 3 (Cell Signaling; 1:750;
#6991), mouse anti-GFP (Roche; 1:1,000). First anti-
bodies were detected with Alexa 488, or 546 conjugated
secondary antibodies (1:1,000; Molecular Probes), fol-
lowed by DAPI-staining.
Microarrays
The facial nuclei were dissected from 300 μm brainstem
sections prepared with a tissue chopper using tungsten nee-
dles. Facial nuclei of four mice/ condition were pooled and
resulted on average between 0.5 and 1 μg RNA. Total RNA
was isolated with the RNeasy kit (Qiagen). RNA of 0.1 μg
was processed on Affymetrix GeneChips (Mouse Gene 1.0
ST array) according to protocols of the Microarray Facility
Tübingen (http://www.microarray-facility.com/cms/index.
php). Raw data normalized to the control sample were ana-
lyzed in such way that only genes with a fold-change of ≥
1.5 (up- or down-regulated) were carried forward. Genes
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were considered SRF-VP16 specific if their fold-change dif-
fered two-fold from the respective factor obtained for SRF-
ΔMADS-VP16.
Quantitative real-time PCR (qPCR)
Total RNA derived from facial nuclei of four animals was
isolated with the RNeasy kit (Qiagen). Reverse transcription
was performed with 0.5 to 1 μg RNA using reverse
transcriptase (Promega) and random hexamers. qPCR was
performed on ABI PRISM 7700 Sequence Detector with
the Power PCR SYBR green PCR master mix (Applied Bio-
systems). Expression was determined in relation to Gapdh
RNA levels. Mouse primers used were as follows: Cnn1
(fwd: GAA GGT CAA TGA GTC AAC TCA GAA; rev:
CCA TAC TTG GTA ATG GCT TTG A), Sprr1a (fwd:
CCT GCT CTT CTC TGA GTA TTA GGA C; rev: GCT
GCT TCA CCT GCT GCT), Atf3 (fwd: GCT GGA GTC
AGT TAC CGT CAA; rev: CGC CTC CTT TTC CTC
TCA T), Gpr151 (fwd: TGA CGT GGA GCA GTT TTG
G; rev: GGG TCA TTG TCT TGT GCT GA), Gal (fwd:
CAG TTT CTT GCA CCT TAA AGA GG; rev: GGT
CTC AGG ACT TCT CTA GGT CTT C), Npy (fwd: AGA
AAA CGC CCC CAG AAC; rev: GAT GAG GGT GGA
AAC TTG GA), Sox11 (fwd: GAG CTG AGC GAG ATG
ATC G; rev: GAA CAC CAG GTC GGA GAA GT), Srf
(fwd: TGT GCA GGC CAT TCA TGT G; rev: ACA GAC
GAC GTC ATG ATG GTG), Egr1 (fwd: GCC GAG CGA
ACA ACC CTA T; rev: TCC ACC ATC GCC TTC TCA
TT), Actn3 (fwd: ACCACTTTGACCGGAAGCG; rev:
GGAGATGAGACAAGCTCGGAA), Acta2 (fwd: CAG
CAA ACA GGA ATA CGA CGA A; rev: TGT GTG CTA
GAG GCA GAG CAG).
Statistics and quantification
Numbers of independent experiments or animals are indi-
cated in figure bars. For all cell culture experiments at least
three independent cultures derived from different animals
were analyzed. For quantification of neuron numbers in fa-
cial nerve injury experiments, all sections (that is 10 to 15
sections/animal) were evaluated. Neurons were scored as
non-degenerated, if they protruded at least one neurite and
if the cell body showed a typical angled shape. For microglia
and T cell numbers 4 to 6 sections/ animal were analyzed.
Statistical significance was calculated using two-tailed t test
or, where appropriate, a one-way analysis of variance
(ANOVA) with a Bonferroni post hoc test.
*, **, and *** indicates P ≤ 0.05, 0.01, and 0.001, re-
spectively. Standard deviation is provided if not men-
tioned otherwise.
Results
SRF-VP16 enhances motorneuron survival in vivo
To investigate a role of SRF in neuron survival, we
employed a well-established model system of neuronal
injury, that is unilateral de-afferentiation of facial motor-
neurons in mice (Figure 1A). The transected facial nerve
was infected with viral particles expressing GFP in addition
to SRF-ΔMADS-VP16 or SRF-VP16. SRF-VP16 consists of
SRF fused to the viral VP16 transactivation domain. To
control for VP16 off-target effects, SRF-ΔMADS-VP16,
lacking DNA binding activity, was used as control [20]. SRF
expression commenced 1 day after infection. Around the
virus injection site of the facial nerve, SRF was also found
in fibroblasts and glial cells, whereas in the facial nucleus -
after retrograde viral transport - SRF expression was motor-
neuron restricted (Figure 1, Additional file 1: Movie S1 and
Additional file 2: Movie S2 and data not shown).
Survival was quantified by analyzing number and
morphology of GFP-positive motorneurons in the facial
nucleus. SRF-VP16 increased the number of surviving
motorneurons compared to SRF-ΔMADS-VP16 (Figure 1,
Additional file 1: Movie S1 and Additional file 2: Movie
S2). At 5 days post viral infection (d.p.i.) and axotomy, the
number of GFP-positive neurons expressing SRF-VP16 or
SRF-ΔMADS-VP16 was comparable (Figure 1B, 1C, and
1H). However, at 25 d.p.i., numbers of surviving SRF-
VP16 positive neurons after transection exceeded
those expressing SRF-ΔMADS-VP16 about three-fold
(Figure 1D-H).
We also inspected motorneuron morphology. SRF-
VP16 expressing neurons appeared less degenerated as
assessed by two parameters: neurite innervation and
shrunk atrophic cell bodies. At 5 d.p.i, SRF-VP16 and
SRF-ΔMADS-VP16 expressing neurons did not differ
with regard to these criteria (Figure 1B, 1C and 1I). At
25 d.p.i about 60% of SRF-ΔMADS-VP16 expressing
neurons lost innervation and acquired a ‘bleb-like’
rounded-up cell morphology (Figure 1D, 1F and 1I). In
contrast, SRF-VP16 suppressed neuronal degeneration,
leaving only 35% of neurons atrophic (Figure 1E, 1G
and 1I).
This suggests that SRF plays a role in survival of axo-
tomized facial motorneurons.
SRF-VP16 suppressed cell death and enhanced neurite
regrowth in vitro
As shown above (Figure 1), SRF-VP16 protects from
motorneuron loss upon facial nerve lesion in vivo. To in-
vestigate whether SRF-VP16 has also an impact on neur-
onal survival of primary neurons we employed an
in vitro assay of axonal injury (Figure 2). Here, neurites
of primary neurons were transected using a micro-scalpel
followed by recording the neuronal response with time-
lapse video-microscopy (Figure 2A-C). VP16 expressing
neurons were identified via GFP-expression. After lesion,
neurites of an SRF-ΔMADS-VP16 expressing neuron did
not re-grow and neurons frequently died (Figure 2A). In
contrast, neurites of an SRF-VP16 expressing neuron
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Figure 1 SRF-VP16 enhances survival of facial motorneurons. (A) (left) The facial nerve is outlined in blue. (right) Virus injection (green) and
position of axotomy is depicted (arrow). Pictures in (B-G) were taken from the facial nucleus whose position is indicated by the red circle. Facial
motorneurons express either SRF-VP16 or SRF-ΔMADS-VP16 along with GFP, whose expression is depicted in (B-G). (B, C) Facial nuclei of an
SRF-ΔMADS-VP16 (B) or SRF-VP16 (C) expressing animal taken at 5 days post infection (d.p.i.) and lesion. No obvious differences were discernable.
(D-G) The facial nucleus of an SRF-ΔMADS-VP16 (D, F) or SRF-VP16 (E, G) infected animal at 25 d.p.i/lesion. In SRF-ΔMADS-VP16 (D, F) compared
to SRF-VP16 (E, G) numbers of surviving neurons are reduced. SRF-ΔMADS-VP16 expressing neurons are atrophic and assume a “bleb-like”
morphology without innervation (see insert in D). SRF-VP16 neurons protrude neurites and cell bodies are squared in shape (insert in E). (H)
Numbers of GFP-positive neurons/section are indicated. (I) At 25 d.p.i., but not 5 d.p.i. SRF-ΔMADS-VP16, in contrast to SRF-VP16 expressing
neurons were degenerated. Dashed lines depict outlines of the facial nuclei. Scale-bar (B-G) = 100 μm; inserts = 10 μm.
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were capable of re-growth, often protruded dynamic
growth cones and survived neurite transection (Figure 2B;
quantification in 2C). Thus, SRF-VP16 enhances neuronal
survival and re-growth of severed neurites in vitro.
In a next step, we investigated potential mechanisms
of SRF’s function in neuronal survival. SRF-VP16 might
modulate motorneuron survival via blocking apoptosis.
To investigate this further, we employed primary neu-
rons assessing protein levels of the pro-apoptotic pro-
tein active caspase-3 upon SRF-VP16 expression
(Figure 2D, 2E). In SRF-ΔMADS-VP16 expressing neu-
rons, active caspase 3 levels were strongly induced. In
contrast SRF-VP16 suppressed this myelin-induced acti-
vation of active caspase-3 (Figure 2D, 2E). Notably, this
effect was more obvious in neurons lacking SRF com-
pared to wild-type neurons (Figure 2D and quantifica-
tion in 2E).
In a further set of experiments we analyzed whether
SRF-VP16 might enhance neuronal survival upon camp-
tothecin induced DNA damage (Figure 2F, 2G). In con-
trol infected primary neurons either expressing GFP
alone or SRF-ΔMADS-VP16, camptothecin induced
apoptosis in a concentration dependent manner. This
was quantified by either counting numbers of active cas-
pase 3 positive (Figure 2F) or numbers of surviving
GFP-positive neurons (Figure 2G). In contrast, SRF-
VP16 expression reduced this camptothecin induced
neuronal cell death compared to control constructs
(Figure 2F, 2G). Thus, in cultures infected with adeno-
viral particles expressing SRF-VP16 (along with GFP)
the number of active caspase 3 positive neurons was
reduced (Figure 2F) whereas more GFP-positive neurons
survived camptothecin treatment (Figure 2G). This find-
ing is in agreement with previous observations made
with wild-type SRF in cortical neurons [6].
Thus, results from primary neurons suggest that SRF-
VP16 might down-regulate expression of pro-apoptotic
proteins to enhance neuronal survival.
SRF-VP16 modulates injury associated immune responses
Neuronal injury is accompanied by immune responses,
for example astrocyte, microglia, and T cell activation
and their subsequent infiltration of lesioned neuronal
tissue. Injury-related immune responses might dampen
as well as exacerbate neuronal loss [18,22]. Regarding
the facial nerve lesion model, peri-neuronal accumula-
tion of microglia cells facilitates axonal regeneration
[23]. Also T cells were assigned important roles for the
immune surveillance during facial nerve injury [24].
Given this important link between an immune response
and neuronal injury, we asked whether SRF-VP16 might
modulate immune responses associated with axon injury
(Figure 3).
Firstly, we inspected microglia activation in the
de-afferented facial nucleus. Microglia were expectedly
elevated at the lesion side compared to the control
side at 5 and 25 d.p.i (Figure 3A, 3E and 3C, 3G;
3M). SRF-VP16 augmented microglia activation in the
lesioned facial nucleus at both time-points compared
to SRF-ΔMADS-VP16 (Figure 3B, 3 and 3D, 3H). Not-
ably, SRF-VP16 also enhanced microglia occupancy
along the facial nerve axons and the axon exit point
(arrows and arrowheads in Figure 3H, respectively;
Figure 3N).
Secondly, we investigated T cells labeled with an anti-
CD3 directed antibody. T cells did not enter the facial
nucleus 5 d.p.i. regardless of virus type (Figure 3O). In
contrast, at 25 d.p.i., we observed T cell infiltration in
lesioned SRF-ΔMADS-VP16 expressing neurons but not
on the uninfected control side (Figure 3I, K, and 3O).
Similar to results obtained on microglia (Figure 3A-H),
SRF-VP16 also enhanced T cell infiltration around
motorneurons and axons (Figure 3L and 3O).
Taken together, microglia and T cell responses are aug-
mented upon SRF-VP16 expression.
Microarray analysis of lesion and SRF-VP16 induced
transcripts
SRF might enhance neuronal survival through various
mechanisms including regulation of survival/apoptosis
related (Figure 2) and immune regulatory genes
(Figure 3). To identify genes modulated by facial nerve
injury per se and by SRF-VP16, we performed transcrip-
tomics after three days of facial nerve lesion (Figures 4
and 5, Table 1 and Additional file 3: Table S1). For this,
facial nuclei of four mice were pooled for each
condition.
Upon lesion only, 1,088 genes (858 up, 230 down)
were regulated more than 1.5-fold compared to un-
lesioned facial nuclei. Figure 4 represents those genes
modulated by facial nerve injury alone regulated by a
factor ≥ 4 (colored in blue). These included reported
genes induced by facial nerve injury such as Atf3, Gal,
Tubb6, Avpr1a, Vip, and Itga7 [18,25]. In addition, we
noted that many genes encoding G-protein coupled
receptors (GPCRs), hormones and small neuropeptides
were modulated by facial nerve axotomy including
Avpr1a, Grm3, Prokr2, Npr3, Gpr161, Gpr133, Gpr84,
Gal, Npy,Vip, and Grp (Figure 4, Table 1, and Additional
file 3: Table S1).
SRF-VP16 specific genes modulated after facial nerve
injury are depicted in red (Figure 4, Table 1). SRF-VP16
modulated two well-known gene sets, IEGs (for example
Egr1, Egr2) and actin cytoskeletal genes (Actc1, Cnn1,
Acta2, and Actn3). Similar to facial nerve injury alone
(see above) we noted that several potential SRF target
genes encoded components of GPCR signaling (F2rl2,
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Figure 2 (See legend on next page.)
Stern et al. Journal of Neuroinflammation 2012, 9:78 Page 6 of 12
http://www.jneuroinflammation.com/content/9/1/78
Glp1r, Rgs4, Crhbp, Nms, Galp; Figure 4 and Table 1).
Finally we observed genes modulated by SRF-VP16
which might link SRF activity to immune responses
investigated above (Figure 1). These include tissue in-
hibitor of metalloproteinase (Timp1), interleukin recep-
tor (Il1r2), galanin-like peptide (Galp), neuromedin
(Nms), and interleukin 1 (Il1f9) (Figure 4, Table 1 and
Additional file 3: Table S1; see also discussion).
To corroborate microarray data (Figure 4), qPCR ana-
lysis of selected genes employing independent cDNA
samples was performed. Indeed fold changes obtained in
this qPCR analysis were comparable to the microarray
data (Figure 5).
Discussion
So far, SRF signaling was not assigned a major role in neur-
onal survival in vivo [15,16] in contrast to injury-related
survival in vitro [6,10,12,26]. This suggests that SRF regu-
lates neuron survival primarily in an injury related situation
rather than in physiological brain development. In accord-
ance, we here demonstrate a neuroprotective SRF-VP16
function in vivo, that is preventing motorneuron degener-
ation upon facial nucleus deafferentiation (Figure 1). Fur-
ther, SRF-VP16 prevented expression of proapoptotic active
caspase 3, enhanced regrowth of severed neurites in vitro
and reduced camptothecin induced apoptosis (Figure 2).
The latter might be directly linked to SRF-VP16 induced
cytoskeletal genes such as actin isoforms (Actc1, Acta2),
calponin (Cnn1), and actinin (Actn3; Figure 4 and Figure 5).
How might SRF-VP16 enhance facial motorneuron
survival?
SRF-VP16 suppressed active caspase 3 in vitro and
reduced camptothecin-induced neuronal cell death
(Figure 2). This SRF-VP16 mediated reduction of active
caspase 3 was stronger in primary neurons lacking SRF
compared to wild-type neurons (Figure 2). Such a reduc-
tion in proapoptotic protein levels by SRF-VP16 might
enhance neuronal survival also upon facial nerve injury
in vivo. To modulate expression of apoptosis related
proteins, SRF-VP16 might recruit IEGs, known regula-
tors of neuronal survival [8], such as Egr-1 and Egr-2
[27] which were induced by SRF-VP16 during facial
nerve lesion (Figures 4 and 5).
In contrast to primary neurons (Figure 2), we did not
observe any major effect of SRF-VP16 compared to SRF-
ΔMADS-VP16 on active caspase 3 and BAX expression
upon facial nerve lesion of wild-type mice in vivo (data
not shown). In addition SRF-VP16 did not alter Ki-67
expression, a proliferation marker. Ki-67 was strongly
induced in lesioned facial motorneurons compared to
unlesioned neurons at 7 days but notably not anymore
at 21 days after lesion (data not shown).
Thus, similar to primary neurons (Figure 2), in vivo
SRF-VP16’s potential to enhance neuronal survival might
be more pronounced and only become visible in the ab-
sence of endogenous wild-type SRF. Indeed it is known
that wild-type SRF competes with SRF-VP16 for access
to certain SRF target gene promoters such as Bcl-2 [8].
Here, SRF-VP16 induced Bcl-2 mRNA levels in SRF-
deficient embryonic stem cells whereas SRF-VP16
failed to induce Bcl-2 in wild-type cells [8].
In sum, using SRF-deficient primary neurons we dem-
onstrate that SRF-VP16 modulates apoptosis in vitro.
Thus it will be useful to employ SRF-deficient mice to
unmask SRF-VP16’s impact on apoptosis also in vivo.
SRF-VP16 enhanced injury associated immune
responses including microglia and T cell activation
(Figure 3). SRF-VP16 enhanced microglia occupancy at
facial nerve axons (Figure 3). In axonal injury, immune
cells such as microglia remove myelin debris and have
neuroprotective potential which might enhance neuronal
survival [22]. Thus, by stimulating microglia and T-cell
number and infiltration in the lesioned FMN and
thereby increasing motorneuron cell body and facial
nerve axon occupancy with these potentially neuropro-
tective immune cells, SRF-VP16 might enhance neuronal
survival.
Of note, SRF-VP16 expression in the facial nucleus was
confined to motorneurons (Figure 1 and Additional file 1:
Movie S1 and Additional file 2: Movie S2). Thus, SRF-VP16
expression in neurons might influence immune cells such
as microglia and T cells via a paracrine mechanism. Such a
paracrine mechanism whereby neuronal SRF affects neigh-
boring cells via regulation of secreted molecules has been
described before, for example in oligodendrocytes [28,29].
With regard to immune responses initiated upon facial
nerve injury such a paracrine mechanism might involve, for
example, cytokine/hormone secretion by neurons. Indeed,
(See figure on previous page.)
Figure 2 SRF-VP16 modulates cell survival in vitro. (A) After lesion, the neurite of an SRF-ΔMADS-VP16 expressing neuron is not re-growing
and the neuron eventually dies after 200 min. The neurite was severed at the position indicated by the arrow. (B) A neuron expressing SRF-VP16.
After transection, neurite growth is observed as well as a dynamic growth cone structure (arrowhead). Eventually at 160 min, the neurite has
exceeded the original lesion position. (C) SRF-VP16 increased the percentage of neurons surviving nerve fiber transection and revealing re-growth
of neurites. (D, E) SRF-VP16 suppressed active caspase 3 levels in wild-type and more pronounced in SRF-deficient neurons compared to neurons
expressing SRF-ΔMADS-VP16. (F, G) SRF-VP16 reduced camptothecin induced neuronal cell death as quantified by counting active caspase 3 (F)
or surviving GFP-positive (G) neurons.
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Figure 3 SRF-VP16 increases microglia and T cell activation in axonal injury. (A-H) Upon axotomy, microglia were activated at both time-
points in the lesioned side expressing SRF-ΔMADS-VP16 compared to the control side (compare C, G with A, E). SRF-VP16 (B, F and D, H)
enhanced microglia activation at both time-points. In addition, SRF-VP16 enhanced microglia association along the axons (arrows in H) and the
nerve exit point (arrowheads in H) at 25 d.p.i. (see insert in H). (I-L) At 25 d.p.i., T cells entered the transected facial nucleus in control infected
animals (K; the insert shows individual T cells), but not the intact facial nucleus (I). In animals expressing SRF-VP16, T cell infiltration was strongly
enhanced in the lesion (L) but not the control side (J). T cells were also found along nerves (L). (M, N) Numbers of microglia/area are indicated
for all conditions in the facial nucleus (M) and along the facial nerve (N). (O) Numbers of T cells/area are indicated for all conditions in the facial
nucleus. Dashed lines depict outlines of the facial nuclei. Dashed boxes point at positions magnified by inserts. Scale-bar (A-L) = 100 μm; inserts
(A-D, K, L) = 20 μm; inserts (E-H) = 100 μm.
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the genome-wide search for SRF-VP16 target genes upon
nerve axotomy provides candidates (Figure 4, Table 1, and
Additional file 3: Table S1). In microarray results presented
in this study (Figures 4 and 5, Table 1, and Additional file 3:
Table S1), facial nuclei of four animals were collected in a
single biological sample. Thus, although we confirmed
some results with independent cDNAs in qPCR (Figure 5),
interpretation of microarray data is limited by a lack of stat-
istical evaluation. Taking this into account, SRF target genes
associated with up-regulated immune responses might in-
clude Il1r2, Galp, Nms, Il1f9, and Timp1. For instance
Timp1, a regulator of matrix metalloproteases activity and
thereby modulator of, for example, microglia migration
[30] is more than 12-fold induced by SRF-VP16 (Table 1).
Figure 4 Transcriptomics of facial nerve injury and SRF-VP16 associated genes. Three days after facial nerve transection, facial nuclei were
subjected to microarray analysis. Genes up- or down-regulated (≥ 4-fold) by facial nerve injury alone are depicted in blue. Genes specifically
altered by SRF-VP16 upon nerve injury are highlighted in red. Genes in black color are modulated by SRF-ΔMADS-VP16. Genes depicted in green
are modulated by lesion alone and SRF-VP16 or SRF-ΔMADS-VP16. Red colors indicate high, whereas blue colors represent low expression. All
expression levels were normalized to the control condition (without lesion).
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Figure 5 Validation of transcriptomics data. cDNAs derived from unlesioned, lesioned, lesioned and SRF-ΔMADS-VP16-positive and lesioned
and SRF-VP16-positive facial nuclei were subjected to qPCR analysis with the indicated primers. Every bar reflects mRNA levels obtained from a
cDNA sample in which facial nuclei of four independent animals were pooled. Numbers of independent cDNAs are indicated at bars. Statistical
significance was calculated in relation to control (no lesion/no virus).
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Conclusions
In sum, this study revealed a first neuroprotective SRF
function during nervous system injury in vivo. SRF is
involved in development and physiological function of
many other organs including liver, skin, muscle, blood ves-
sels, and, for example, the heart [9]. Thus, SRF might also
be involved in survival and cellular regeneration processes
of other injured organs besides the nervous system.
Additional Files
Additional flie 1: Movie S1. GFP expression in the nucleus facialis
infected with Ad-SRF-VP16.
Additional file 2: Movie S2. GFP expression in the nucleus facialis
infected with Ad-SRF-ΔMADS-VP16.
Additional file 3: Table S1. Raw and processed data of transcriptomics.
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Table 1 Summary of genes most strongly regulated by lesion only or SRF-VP16
Lesion-specific genes SRF-VP16-specific genes
Gene name Gene symbol Up Gene name Gene symbol Up
1 Small proline-rich protein 2J Sprr2j 80.1 Actin, alpha, cardiac Actc1 13.2
2 G protein-coupled receptor 151 Gpr151 31.0 Protein phosphatase with EF hand Ppef1 12.2
3 Activating transcription factor 3 Atf3 28.6 Tissue inhibitor of metalloprot. 1 Timp1 12.2
4 Glutamate receptor, metab. 3 Grm3 24.9 Ankyrin repeat domain 1 Ankrd1 10.3
5 Protein phosphatase with EF Ppef1 19.9 Calponin 1 Cnn1 9.5
6 Galanin Gal 19.8 Coagulation factor II receptor-like 2 F2rl2 8.7
7 Tissue inhibitor of metalloprot. 1 Timp1 14.3 Actin, alpha 2, smooth muscle Acta2 7.9
8 Neuropeptide Y Npy 13.2 Transgelin (Sm22) Tagln 6.4
9 Annexin a10 Anxa10 12.7 Apolipoprotein L 7b | L 7e Apol7b/e 4.7
10 Small proline-rich protein 2 J Sprr2j 12.7 Serine (or cysteine) peptidase inh. Serpine1 4.5
11 Tubulin, beta 6 Tubb6 11.4 T-box18 Tbx18 3.8
12 Ankyrin repeat domain 1 Ankrd1 11.4 Interleukin 1 receptor, type II Il1r2 3.8
13 Wingless related 2b Wnt2b 10.6 Actinin alpha 3 Actn3 3.7
14 A disintegrin and metallopept. 8 Adam8 9.5 Angiopoietin-like 2 Angptl2 3.4
15 S100 calcium binding prot. A11 S100a11 9.2 Insulin-like growth fac. bind. prot. 6 Igfbp6 3.2
16 Xanthine dehydrogenase Xdh 8.7 Follistatin Fst 3.2
17 Anthrax toxin receptor 2 Antxr2 8.5 GLI pathogenesis-related 1 Glipr1 3.1
18 SH2 domain protein 1B2 Sh2d1b2 8.4 Solute carrier family 38, member 8 Slc38a8 2.9
19 Gastrin releasing peptide Grp 7.5 Early growth response 1 Egr1 2.7
20 Vasoactive intestinal polypeptide Vip 7.4 Dihydroxyacetone kinase 2 hom. Dak 2.7
21 Protein C receptor, endothelial Procr 6.9 Tuftelin 1 Tuft1 2.6
22 Integrin alpha 7 Itga7 6.8 Serum response factor Srf 2.4
23 Lymphocyte antigen 86 Ly86 6.8 Bone marrow stromal cell antigen 1 Bst1 2.4
24 Nerve growth factor Ngf 6.5 Dopamine receptor 2 Drd2 2.4
25 Integrin alpha M Itgam 6.1 Desmocollin 3 Dsc3 2.3
26 Prokineticin receptor 2 Prokr2 6.0 Blood vessel epicardial substance Bves 2.2
27 Serine (or cysteine) pept. inh. Serpine1 5.9 ALX homeobox 1 Alx1 2.2
28 G protein-coupled receptor 133 Gpr133 5.7 Neuronal pentraxin 2 Nptx2 2.2
29 Cyclin-dep. kinase inh.1A (P21) Cdkn1a 5.6 Glucagon-like peptide 1 receptor Glp1r 1.9
30 GalaninCD180 antigen Cd180 5.4 Regulator of G-protein signaling 4 Rgs4 1.7
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